Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharmaceuticals on Multi-Million Dollar Licensing Agreement with Cipher Pharmaceuticals
Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharmaceuticals on Multi-Million Dollar Distribution Agreement with Cipher Pharmaceuticals
New York – April 1, 2015 – Securities and Corporate law firm Sichenzia Ross Friedman Ference LLP has announced today that the Firm represented Can-Fite Biopharmaceuticals Ltd., (NYSE MKT: CANF) an Israeli biopharmaceutical company developing therapeutic products, in a multi million dollar Distribution Agreement where Cipher Pharmaceuticals, Inc. will distribute Can-Fite’s leading drug candidate, CF101 in the Canadian market for certain indications upon receipt of regulatory approval.
The Sichenzia Ross Friedman Ference LLP team was led by Partner Greg Sichenzia and Gary Emmanuel.
- Sichenzia Ross Ference LLP Represents EzFill in $28.75 Million Initial Public Offering and NASDAQ Listing - September 20, 2021
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $81 Million Underwritten Public Offering for Farmmi, Inc. - September 15, 2021
- Sichenzia Ross Ference LLP Secures Deferred Prosecution Agreement for Client Under Federal Indictment in the Southern District of New York - September 13, 2021